IL323185A - Methods for the preparation and dose regimens for use of sstr4 agonists and salts thereof - Google Patents

Methods for the preparation and dose regimens for use of sstr4 agonists and salts thereof

Info

Publication number
IL323185A
IL323185A IL323185A IL32318525A IL323185A IL 323185 A IL323185 A IL 323185A IL 323185 A IL323185 A IL 323185A IL 32318525 A IL32318525 A IL 32318525A IL 323185 A IL323185 A IL 323185A
Authority
IL
Israel
Prior art keywords
compound
dose
administered
patient
yield
Prior art date
Application number
IL323185A
Other languages
Hebrew (he)
Inventor
William Brian Kielbasa
Scott Alan Monk
Eric Michael Pearlman
David Michael Remick
John Robert Rizzo
Original Assignee
Lilly Co Eli
William Brian Kielbasa
Scott Alan Monk
Eric Michael Pearlman
David Michael Remick
John Robert Rizzo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, William Brian Kielbasa, Scott Alan Monk, Eric Michael Pearlman, David Michael Remick, John Robert Rizzo filed Critical Lilly Co Eli
Publication of IL323185A publication Critical patent/IL323185A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Description

WO 2024/191686 PCT/US2024/018624 H H HN , or a pharmaceutically acceptable salt thereof, and/or ahydrate thereof. id="p-23" id="p-23" id="p-23" id="p-23"
[0023] Also disclosed herein is a method of treating pain in a patient in need oftreatment thereof, the method comprising administering to the patient a dose of about 25mg to about 1400 mg per dose of a compound of the formula: H H HN OH O HO. OH O OH id="p-24" id="p-24" id="p-24" id="p-24"
[0024] Also disclosed herein is a method of treating neuropathic pain in a patientin need of treatment thereof, the method comprising administering to the patient a dose ofabout 50 mg to about 600 mg per dose of a compound of the formula: H H HN OH O HO. OH O OH id="p-18" id="p-18" id="p-18" id="p-18"
[0018] Also disclosed herein is a method of treating pain in a patient in need oftreatment thereof, the method comprising administering to the patient a dose of about 25mg to about 1400 mg per dose of a compound of the formula: H H HN OH O HO. OH O OH ■ 1.5 H O id="p-19" id="p-19" id="p-19" id="p-19"
[0019] Also disclosed herein is a method of treating neuropathic pain in a patientin need of treatment thereof, the method comprising administering to the patient a dose ofabout 50 mg to about 600 mg per dose of a compound of the formula: H H HN OH O HO. OH O OH ■ 1.5 H O WO 2024/191686 PCT/US2024/018624 2 mixing the intermediate compound with to yield H H O ISiioand H H O Iii NSiioremoving tosyl function group from to yieldthe compound. id="p-22" id="p-22" id="p-22" id="p-22"
[0022] Also disclosed herein is a product comprising a compound, such as(lR,5S,6r)-N-(2-methyl-l-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide L-tartrate sesquihydrate, preparared by themethod described herein.
DETAILED DESCRIPTION OF THE INVENTION[0028] SSTR4 Agonists[0029] The disclosed method can be used to prepare the compounds of Formula I.The disclosed method can also be used to prepare salts, solvates, hydrates, and/orcombinations thereof of Formula I. id="p-30" id="p-30" id="p-30" id="p-30"
[0030][0031] Formula I. SSTR4 Agonist, (lR,5S,6r)-N-(2-methyl-l-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-azabicyclo[3.1,0]hexane-6-carboxamide

Claims (68)

CLAIMS What is claimed is:
1. A method of treating pain in a patient in need of treatment thereof, the method comprising administering to the patient a dose of about 25 mg to about 1400 mg per dose of (1R,5S,6r)-N-(2-Methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide, or a pharmaceutically acceptable salt thereof, and/or a hydrate thereof.
2. The method of claim 1, wherein the compound is of the formula: , or a hydrate thereof.
3. The method of claim 1 or 2, wherein the compound is of the formula: .
4. The method of claim 1 or 2, wherein the compound is of the formula: .
5. The method of any one of claims 1 to 4, wherein the dose is administered to the patient once daily, twice daily, every 24 hours, every 12 hours, every 8 hours, every hours, or every 4 hours.
6. The method of any one of claims 1 to 5, wherein the dose is administered to the patient twice daily.
7. The method of any one of claims 1 to 6, wherein the dose administered to the patient is from about 50 mg to about 600 mg.
8. The method of any one of claims 1 to 7, wherein the dose administered to the patient is about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, or about 600 mg.
9. The method of any one of claims 1 to 8, wherein the dose administered to the patient is about 50 mg and the dose is administered twice daily.
10. The method of any one of claims 1 to 8, wherein the dose administered to the patient is about 100 mg and the dose is administered twice daily.
11. The method of any one of claims 1 to 8, wherein the dose administered to the patient is about 200 mg and the dose is administered twice daily.
12. The method of any one of claims 1 to 8, wherein the dose administered to the patient is about 300 mg and the dose is administered twice daily.
13. The method of any one of claims 1 to 8, wherein the dose administered to the patient is about 400 mg and the dose is administered twice daily.
14. The method of any one of claims 1 to 8, wherein the dose administered to the patient is about 500 mg and the dose is administered twice daily.
15. The method of any one of claims 1 to 8, wherein the dose administered to the patient is about 600 mg and the dose is administered twice daily.
16. The method of any one of claims 1 to 15, wherein the pain comprises osteoarthritic pain, chronic lower back pain, or neuropathic pain.
17. The method of any one of claims 1 to 16, wherein the pain comprises neuropathic pain.
18. The method of claim 17, wherein the neuropathic pain comprises diabetic neuropathy, polyneuropathy, distal sensory polyneuropathy, peripheral neuropathy, central neuropathy, diabetic peripheral neuropathy, or mixed neuropathy.
19. The method of any one of claims 1 to 18, wherein the compound is administered to the patient in a tablet composition, a capsule composition, or an aqueous solution.
20. The method of claim 19, wherein the capsule composition comprises microcrystalline cellulose, silica dioxide, or combination thereof.
21. A capsule composition comprising a compound of the formula: , or a hydrate thereof.
22. The composition of claim 21, wherein the compound is of the formula: .
23. The composition of claim 21 or 22, wherein the capsule composition further comprises microcrystalline cellulose, silica dioxide, or combination thereof.
24. The composition of any one of claims 21 to 23, wherein the composition comprises from about 50 mg to about 600 mg of the compound.
25. The composition of any one of claims 21 to 24, wherein the composition comprises from about 50 mg to about 200 mg of the compound.
26. The composition of any one of claims 21 to 25, wherein the composition comprises about 50 mg of the compound.
27. The composition of any one of claims 21 to 26, wherein the composition comprises about 200 mg of the compound.
28. A method for preparing (1R,5S,6r)-N-(2-Methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide, or pharmaceutically acceptable salts thereof; and the method comprising: mixing a compound of the formula: , wherein R is a C1 to C6 alkyl, with a sulfonium salt of the formula: , wherein X is a halogen and A is an anion to yield an intermediate compound of the formula: ; mixing the intermediate compound with to yield ; and removing tosyl function group from to yield the compound.
29. The method of claim 28, wherein the method comprises: mixing a compound of the formula: , with a sulfonium salt of the formula: , to yield the intermediate compound.
30. The method of claim 28 or 29, wherein the method comprises less than 8 synthetic steps.
31. The method of any one of claims 28 to 30, wherein the method does not include a metal catalyst.
32. The method of any one of claims 28 to 31, wherein the method does not utilize a hydride salt.
33. The method of any one of claims 28 to 32, wherein the method comprises: (a) mixing with to yield ; (b) mixing with trifluoroacetic acid to yield ; and (c) mixing with , to yield the intermediate compound.
34. The method of claim 33, wherein the method further comprises: (d) mixing the intermediate compound with to yield ; and (e) mixing with potassium diphenylphosphine to yield the compound, or a pharmaceutically acceptable salt thereof and/or a hydrate thereof.
35. The method of any one of claims 28 to 35, wherein the method comprises: (a) mixing methyl (E) 4-bromobut-2-enoate with tert-Butyl tosylcarbamate to yield methyl (E)-4-((N-(tert-butoxycarbonyl)-4-methylphenyl)sulfonamido)but-2-enoate; (b) mixing methyl (E)-4-((N-(tert-butoxycarbonyl)-4-methylphenyl)sulfonamido)but-2-enoate with trifluoroacetic acid to yield methyl (E)-4-((4-methylphenyl)sulfonamido)but-2-enoate; (c) mixing methyl (E)-4-((4-methylphenyl)sulfonamido)but-2-enoate with 2-bromoethyl)diphenylsulfonium triflate to yield the intermediate compound; (d) mixing the intermediate compound with 2-Methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-amine to yield (1R,5S,6r)-N-(2-Methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-tosyl-3-azabicyclo[3.1.0]hexane-6-carboxamide; (e) mixing ((1R,5S,6r)-N-(2-Methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-tosyl-3-azabicyclo[3.1.0]hexane-6-carboxamide with potassium diphenylphosphine to yield the compound, or a pharmaceutically acceptable salt thereof and/or a hydrate thereof.
36. The method of any one of claims 28 to 35, wherein the compound is selected from , , , , or combinations thereof.
37. The method of any one of claims 28 to 36, wherein the method further comprises: (f) mixing the compound with L-tartaric acid, citric acid, L-malic acid, or a combination thereof.
38. A method for preparing an intermediate compound of the formula: or pharmaceutically acceptable salts thereof; and the method comprising: mixing a compound of the formula: , wherein R is a C1 to C6 alkyl, with a sulfonium salt of the formula: , wherein X is a halogen and A is an anion to yield the intermediate compound.
39. The method of claim 38, wherein the method comprises: mixing a compound of the formula: , with a sulfonium salt of the formula: , to yield the intermediate compound, or a pharmaceutically acceptable salt thereof.
40. The method of claim 38 or 39, wherein the method comprises less than 8 synthetic steps.
41. The method of any one of claims 38 to 40, wherein the method does not include a metal catalyst.
42. The method of any one of claims 38 to 41, wherein the method does not utilize a hydride salt.
43. The method of any one of claims 38 to 42, wherein the method comprises: (a) mixing with to yield ; (b) mixing with trifluoroacetic acid to yield ; and (c) mixing with , to yield the intermediate compound, or a pharmaceutically acceptable salt thereof.
44. The method of any one of claims 38 to 43, wherein the method comprises: (a) Mixing methyl (E) 4-bromobut-2-enoate with tert-Butyl tosylcarbamate to yield methyl (E)-4-((N-(tert-butoxycarbonyl)-4-methylphenyl)sulfonamido)but-2-enoate; (b) Mixing methyl (E)-4-((N-(tert-butoxycarbonyl)-4-methylphenyl)sulfonamido)but-2-enoate with trifluoroacetic acid to yield methyl (E)-4-((4-methylphenyl)sulfonamido)but-2-enoate; and (c) Mixing methyl (E)-4-((4-methylphenyl)sulfonamido)but-2-enoate with 2-bromoethyl)diphenylsulfonium triflate to yield the intermediate compound, or a pharmaceutically acceptable salt thereof.
45. A compound of (1R,5S,6r)-N-(2-Methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide, or a pharmaceutically acceptable salts thereof and/or a hydrate thereof, wherein the compound is prepared by the method of any one of claims 28 to 37.
46. The compound of claim 45, wherein the compound is of the formula: , , , , or combinations thereof.
47. A compound prepared by the method of any one of claims 28 to 37, wherein the compound is (1R,5S,6r)-N-(2-Methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide, or a pharmaceutically acceptable salt thereof and/or a hydrate thereof.
48. The compound of claim 47, wherein the compound is selected from: , , , , or combinations thereof.
49. A compound of (1R,5S,6r)-N-(2-Methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide, or a pharmaceutically acceptable salt thereof, and/or a hydrate thereof; for use in the treatment of pain in a patient in need of treatment thereof, wherein the compound is administered in a dose of about 25 mg to about 1400 mg per dose.
50. The comound of claim 49, wherein the compound is of the formula: , or a hydrate thereof.
51. The compound of claim 49 or 50, wherein the compound is of the formula: .
52. The compound of claim 49 or 50, wherein the compound is of the formula: .
53. The compound of any one of claims 49 to 52, wherein the dose is administered to the patient once daily, twice daily, every 24 hours, every 12 hours, every 8 hours, every hours, or every 4 hours.
54. The compound of any one of claims 49 to 53, wherein the dose is administered to the patient twice daily.
55. The compound of any one of claims 49 to 54, wherein the dose administered to the patient is from about 50 mg to about 600 mg.
56. The compound of any one of claims 49 to 55, wherein the dose administered to the patient is about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, or about 600 mg.
57. The compound of any one of claims 49 to 56, wherein the dose administered to the patient is about 50 mg and the dose is administered twice daily.
58. The compound of any one of claims 49 to 56, wherein the dose administered to the patient is about 100 mg and the dose is administered twice daily.
59. The compound of any one of claims 49 to 56, wherein the dose administered to the patient is about 200 mg and the dose is administered twice daily.
60. The compound of any one of claims 49 to 56, wherein the dose administered to the patient is about 300 mg and the dose is administered twice daily.
61. The compound of any one of claims 49 to 56, wherein the dose administered to the patient is about 400 mg and the dose is administered twice daily.
62. The compound of any one of claims 49 to 56, wherein the dose administered to the patient is about 500 mg and the dose is administered twice daily.
63. The compound of any one of claims 49 to 56, wherein the dose administered to the patient is about 600 mg and the dose is administered twice daily.
64. The compound of any one of claims 49 to 63, wherein the pain comprises osteoarthritic pain, chronic lower back pain, or neuropathic pain.
65. The compound of any one of claims 49 to 64, wherein the pain comprises neuropathic pain.
66. The compound of claim 65, wherein the neuropathic pain comprises diabetic neuropathy, polyneuropathy, distal sensory polyneuropathy, central neuropathy, diabetic peripheral neuropathy, or mixed neuropathy.
67. The compound of any one of claims 49 to 66, wherein the compound is administered to the patient in a tablet composition, a capsule composition, or an aqueous solution.
68. The compound of claim 67, wherein the capsule composition comprises microcrystalline cellulose, silica dioxide, or combination thereof.
IL323185A 2023-03-10 2025-09-04 Methods for the preparation and dose regimens for use of sstr4 agonists and salts thereof IL323185A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363489563P 2023-03-10 2023-03-10
PCT/US2024/018624 WO2024191686A1 (en) 2023-03-10 2024-03-06 Methods for the preparation and dose regimens for use of sstr4 agonists and salts thereof

Publications (1)

Publication Number Publication Date
IL323185A true IL323185A (en) 2025-11-01

Family

ID=90572161

Family Applications (1)

Application Number Title Priority Date Filing Date
IL323185A IL323185A (en) 2023-03-10 2025-09-04 Methods for the preparation and dose regimens for use of sstr4 agonists and salts thereof

Country Status (10)

Country Link
US (1) US20240307349A1 (en)
EP (1) EP4676477A1 (en)
JP (2) JP7569953B2 (en)
KR (1) KR20250156812A (en)
CN (1) CN120835784A (en)
AU (1) AU2024236692A1 (en)
IL (1) IL323185A (en)
MX (1) MX2025010658A (en)
TW (1) TW202500127A (en)
WO (1) WO2024191686A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025193591A1 (en) * 2024-03-11 2025-09-18 Eli Lilly And Company Crystalline form of a tartrate salt of an sstr4 agonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
CN113717167B (en) 2020-05-21 2022-12-02 广州费米子科技有限责任公司 Fused ring compound, preparation method thereof, pharmaceutical composition and application
TWI910192B (en) 2020-07-13 2026-01-01 大陸商廣州費米子科技有限責任公司 Nitrogen-containing heterocyclic compound, pharmaceutical composition and use thereof
TWI860849B (en) * 2021-09-14 2024-11-01 美商美國禮來大藥廠 Sstr4 agonist salts

Also Published As

Publication number Publication date
JP7569953B2 (en) 2024-10-18
CN120835784A (en) 2025-10-24
WO2024191686A1 (en) 2024-09-19
TW202500127A (en) 2025-01-01
EP4676477A1 (en) 2026-01-14
US20240307349A1 (en) 2024-09-19
AU2024236692A1 (en) 2025-10-16
JP2024170613A (en) 2024-12-10
JP2024133445A (en) 2024-10-02
KR20250156812A (en) 2025-11-03
MX2025010658A (en) 2025-10-01

Similar Documents

Publication Publication Date Title
RU2527337C9 (en) Stabilised composition containing at least one adrenergic compound
CA2878370C (en) Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension
JP4934653B2 (en) Glaucoma treatment agent comprising Rho kinase inhibitor and β-blocker
AU2011285928B2 (en) Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US8846765B2 (en) Pharmaceutical combination
US9339496B2 (en) Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
JP4482726B2 (en) Glaucoma treatment agent comprising Rho kinase inhibitor and prostaglandins
TW201338772A (en) Pharmaceutical combinations
MX2012008516A (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect.
WO2013154347A1 (en) Liquid formulation for oral administration comprising ambroxol, levodropropizine and buffering agent, and method for preparing the same
WO2016004056A1 (en) Pharmaceutical combinations
AU725577B2 (en) Smooth muscle spasmolytic agents, compositions and methods of use thereof
JPWO2012099142A1 (en) Bromfenac aqueous liquid composition having storage efficacy
WO2021049519A1 (en) METHOD FOR PREVENTING PRECIPITATION OF INJECTABLE SOLUTION CONTAINING p-BORONOPHENYLALANINE
RU2483731C1 (en) Solution for injections containing nalbuphine
JP2019526549A (en) Ophthalmic pharmaceutical composition with improved storage efficacy or photostability
JP7066909B1 (en) Aqueous eye drops containing high molecular weight compounds, silver salts and ionic isotonic agents
JP2012250953A (en) Combination of adenosine derivative and alpha2 receptor agonist
JP2004509144A (en) 1-Amino-alkylcyclohexanes as trypanocidal agents
US20210085636A1 (en) THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING FP AGONIST AND ß BLOCKER
TWI917308B (en) Omidenepag combination
JPWO2007074904A1 (en) Aqueous pharmaceutical composition
HK40033075A (en) THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING FP AGONIST AND β BLOCKER
RS20100189A (en) New procedures for formulation of preparation for local analgesia in dentistry
JP2012250948A (en) Combination of adenosine derivative and carbonic anhydrase inhibitor